
Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination tivozanib and nivolumab in for renal cell carcinoma (RCC) in the TiNivo-2 study, according to a poster presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium by Katy Beckermann, MD, PhD.